Cargando…
Immunogenicity Analysis of PCV3 Recombinant Capsid Protein Virus-like Particles and Their Application in Antibodies Detection
Porcine circovirus type 3 is a newly emerging pathogen of porcine circovirus associated disease (PCVAD). Currently, there is no commercially available vaccine, resulting in huge economic losses to the pig industry. Porcine circovirus type 3 capsid protein (Cap) can self-assemble into virus-like part...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299735/ https://www.ncbi.nlm.nih.gov/pubmed/37373524 http://dx.doi.org/10.3390/ijms241210377 |
_version_ | 1785064437296660480 |
---|---|
author | Cao, Xuyang Huang, Min Wang, Ying Chen, Yanzhi Yang, Hanwen Quan, Fusheng |
author_facet | Cao, Xuyang Huang, Min Wang, Ying Chen, Yanzhi Yang, Hanwen Quan, Fusheng |
author_sort | Cao, Xuyang |
collection | PubMed |
description | Porcine circovirus type 3 is a newly emerging pathogen of porcine circovirus associated disease (PCVAD). Currently, there is no commercially available vaccine, resulting in huge economic losses to the pig industry. Porcine circovirus type 3 capsid protein (Cap) can self-assemble into virus-like particles (VLPs). Therefore, the expression of the recombinant Cap protein is of great significance for the prevention, diagnosis and control of porcine circovirus type 3 associated diseases. In this study, the recombinant Cap protein was successfully expressed in Escherichia coli by deleting the nuclear localization sequence (NLS). The VLPs were observed by transmission electron microscopy. To evaluate the immunogenicity of the recombinant Cap protein, mice were immunized. As a result, the recombinant Cap protein can induce higher levels of humoral and cellular immune responses. A VLP-based ELISA method was developed for the detection of antibodies. The established ELISA method has good sensitivity, specificity, repeatability and clinical applicability. These results demonstrate the successful expression of the PCV3 recombinant Cap protein and the preparation of recombinant Cap protein VLPs, which can be used for the preparation of subunit vaccines. Meanwhile, the established I-ELISA method lays a foundation for the development of the commercial PCV3 serological antibody detection kit. |
format | Online Article Text |
id | pubmed-10299735 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102997352023-06-28 Immunogenicity Analysis of PCV3 Recombinant Capsid Protein Virus-like Particles and Their Application in Antibodies Detection Cao, Xuyang Huang, Min Wang, Ying Chen, Yanzhi Yang, Hanwen Quan, Fusheng Int J Mol Sci Article Porcine circovirus type 3 is a newly emerging pathogen of porcine circovirus associated disease (PCVAD). Currently, there is no commercially available vaccine, resulting in huge economic losses to the pig industry. Porcine circovirus type 3 capsid protein (Cap) can self-assemble into virus-like particles (VLPs). Therefore, the expression of the recombinant Cap protein is of great significance for the prevention, diagnosis and control of porcine circovirus type 3 associated diseases. In this study, the recombinant Cap protein was successfully expressed in Escherichia coli by deleting the nuclear localization sequence (NLS). The VLPs were observed by transmission electron microscopy. To evaluate the immunogenicity of the recombinant Cap protein, mice were immunized. As a result, the recombinant Cap protein can induce higher levels of humoral and cellular immune responses. A VLP-based ELISA method was developed for the detection of antibodies. The established ELISA method has good sensitivity, specificity, repeatability and clinical applicability. These results demonstrate the successful expression of the PCV3 recombinant Cap protein and the preparation of recombinant Cap protein VLPs, which can be used for the preparation of subunit vaccines. Meanwhile, the established I-ELISA method lays a foundation for the development of the commercial PCV3 serological antibody detection kit. MDPI 2023-06-20 /pmc/articles/PMC10299735/ /pubmed/37373524 http://dx.doi.org/10.3390/ijms241210377 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cao, Xuyang Huang, Min Wang, Ying Chen, Yanzhi Yang, Hanwen Quan, Fusheng Immunogenicity Analysis of PCV3 Recombinant Capsid Protein Virus-like Particles and Their Application in Antibodies Detection |
title | Immunogenicity Analysis of PCV3 Recombinant Capsid Protein Virus-like Particles and Their Application in Antibodies Detection |
title_full | Immunogenicity Analysis of PCV3 Recombinant Capsid Protein Virus-like Particles and Their Application in Antibodies Detection |
title_fullStr | Immunogenicity Analysis of PCV3 Recombinant Capsid Protein Virus-like Particles and Their Application in Antibodies Detection |
title_full_unstemmed | Immunogenicity Analysis of PCV3 Recombinant Capsid Protein Virus-like Particles and Their Application in Antibodies Detection |
title_short | Immunogenicity Analysis of PCV3 Recombinant Capsid Protein Virus-like Particles and Their Application in Antibodies Detection |
title_sort | immunogenicity analysis of pcv3 recombinant capsid protein virus-like particles and their application in antibodies detection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299735/ https://www.ncbi.nlm.nih.gov/pubmed/37373524 http://dx.doi.org/10.3390/ijms241210377 |
work_keys_str_mv | AT caoxuyang immunogenicityanalysisofpcv3recombinantcapsidproteinviruslikeparticlesandtheirapplicationinantibodiesdetection AT huangmin immunogenicityanalysisofpcv3recombinantcapsidproteinviruslikeparticlesandtheirapplicationinantibodiesdetection AT wangying immunogenicityanalysisofpcv3recombinantcapsidproteinviruslikeparticlesandtheirapplicationinantibodiesdetection AT chenyanzhi immunogenicityanalysisofpcv3recombinantcapsidproteinviruslikeparticlesandtheirapplicationinantibodiesdetection AT yanghanwen immunogenicityanalysisofpcv3recombinantcapsidproteinviruslikeparticlesandtheirapplicationinantibodiesdetection AT quanfusheng immunogenicityanalysisofpcv3recombinantcapsidproteinviruslikeparticlesandtheirapplicationinantibodiesdetection |